Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
February 08, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
February 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
February 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
February 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
January 31, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
January 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
January 18, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
January 10, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
December 22, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conference
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
December 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
December 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
December 13, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
December 11, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
December 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
November 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
November 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
November 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conference
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
RCUS
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
November 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
November 09, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
November 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
October 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.